Closing the Brief Case: A Travelers Tale--Burkholderia pseudomallei Infection in a Cystic Fibrosis Patient The Brief Case
PMID: 31977412 [PubMed - in process]
Despite our differences, one thing we all have in common is death. One way or another, it's going to get each of us. Jeremie has been forced to meditate on that reality and it's had a profound effect on how he approaches life. In this keynote, Jeremie candidly and openly shares his story about growing up with Cystic Fibrosis and how he found laughter to be key as he shifted his perspective from seeing himself as someone who is dying from a fatal disease to someone who has been given the gift of a shortened life expectancy in order to make the most of it.
Trikafta, a combination of elexacaftor, ivacaftor, and tezacaftor, is a new drug for the treatment of the most common cystic fibrosis mutation.Serious adverse effects include elevated liver enzymes and an increased risk of cataracts.
CONCLUSION: Use of the CFTR modulator lumacaftor/ivacaftor was associated with significantly lower hepatic steatosis. No association between CFRD and hepatic steatosis was found in this cohort. PMID: 31966908 [PubMed]
A BEAMING Harriet Corr holds up her first box of life-saving cystic fibrosis pills, after a year of melting hearts in the Daily Express.
In this study we found blocking autophagy led to increased CP growth in both macrophages and mouse embryonic fibroblasts. In vivo, loss of the autophagy elongation component ATG16L1 specifically in myeloid cells led to increased mortality in response to CP infection, characterized by greater numbers of neutrophils and dendritic cells, but no change in the CP burden in the lungs. This was accompanied by an increase in inflammasome-active macrophages and IL-1β production. While induction of autophagy in macrophages led to reduced CP growth in vitro, in vivo treatment with rapamycin led to increased mortality of infected...
Publication date: Available online 19 September 2018Source: Microbial PathogenesisAuthor(s): Hizbullah, Zarghoona Nazir, Sahib Gul Afridi, Mohibullah Shah, Sulaiman Shams, Asifullah KhanAbstractThe Burkholderia pseudomallei is a unique bio-threat and causative agent of melioidosis. The B. pseudomallei Bp1651 strain has been isolated from a chronic cystic fibrosis patient. The genome-level DNA sequences information of this strain has recently been published. Unfortunately, there is no commercial vaccine available till date to combat B. pseudomallei infection. The genome-wide prioritization approaches are widely used for the...
Burkholderia pseudomallei is the causative agent of melioidosis, which is a potentially life threatening disease endemic in Southeast Asian countries. In Malaysia, cystic fibrosis (CF) is an uncommon condition. T...
Conclusion: Chronic carriage of B. pseudomallei in patients with CF appears common after infection, in contrast to the non-CF population. This is often associated with an accelerated clinical decline. Lung transplantation has been performed in select cases of chronic B. pseudomallei infection.